8. Warrants

As of June 30, 2026, the number of shares of common stock issuable upon the exercise of outstanding warrants consisted of the following:

​

​

2019 Warrants

In connection with a public offering that the Company completed on February 5, 2019, the Company issued immediately exercisable warrants (the “2019 Warrants”) to investors. The 2019 Warrants had an exercise price of $19.50 per share and during the six months ended June 30, 2026, the 2019 Warrants expired.

March 2020 Pre-funded Warrants

In March 2020, the Company’s stockholders approved the conversion of the Series A Preferred Stock into a pre-funded warrant to purchase shares of common stock at an exercise price of $0.001 (the “March 2020 Pre-funded Warrants”). During the six months ended June 30, 2025, 824,718 March 2020 Pre-funded Warrants were cashless exercised, resulting in the issuance of 809,558 common shares of the Company’s common stock.

September 2021 Pre-funded Warrants

In September 2021, the Company completed a public offering, whereby the Company issued pre-funded warrants to purchase shares of its common stock (the “September 2021 Pre-funded Warrants”) to certain investors. During the six months ended June 30, 2025, 591,603 September 2021 Pre-funded warrants were cashless exercised, resulting in the issuance of 590,424 common shares of the Company’s common stock.

January 2023 Common Stock Warrants

In January 2023, in connection with Leap’s acquisition of Flame Biosciences LLC (“Flame”), the warrants held by the Flame warrant holders became exercisable for 6,530 shares of the Company’s common stock (the “January 2023 Common Stock Warrants”). The January 2023 Common Stock Warrants had an exercise price of $6.78 per share and expired in February 2025.

January 2023 Series X Preferred Stock Warrants

In January 2023, in connection with Leap’s acquisition of Flame, the warrants held by the Flame warrant holders also became exercisable for 443 shares of Series X Preferred Stock (the “January 2023 Series X Preferred Stock Warrants”). Following stockholder approval, each share of Series X Preferred Stock converted into 100 shares of common stock during the three months ended June 30, 2023. The January 2023 Series X Preferred Stock Warrants had an exercise price of $6.78 per share and expired in February 2025.

April 2024 Pre-funded Warrants

In April 2024, the Company issued pre-funded warrants to purchase shares of common stock (the “April 2024 Pre-funded Warrants) as part of a private placement. During the six months ended June 30, 2025, 1,523,404 April 2024 Pre-funded Warrants were cashless exercised, resulting in the issuance of 1,521,059 common shares of the Company’s common stock.

October 2025 Pre-funded Warrants

In October 2025, the Company completed a private placement, whereby it issued the October 2025 Pre-Funded Warrants (as defined below in Note 9) to purchase up to an aggregate of 80,768,504 shares of the Company’s common stock. The October 2025 Pre-Funded Warrants have an exercise price of $0.001 per share, each exercisable for one share of the Company’s common stock. The exercise price and the number of shares of common stock issuable upon exercise of each pre-funded warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the common stock. The October 2025 Pre-Funded Warrants qualify for equity classification.

October 2025 Common Stock Warrants

In October 2025, the Company completed a private placement (the “October 2025 Private Placement”), whereby the Company issued the October 2025 Common Warrants-Investors (as defined below in Note 9) to purchase up to an aggregate of 71,985,605 shares of Company common stock, each exercisable for one share of common stock at an exercise price of $0.5335 per common warrant share. The October 2025 Common Warrants are exercisable in cash or by means of a cashless exercise. They expire on the tenth anniversary of their date of issuance and qualify for equity classification. The exercise price and the number of shares of common stock issuable upon exercise of each common warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock combinations, or similar events affecting the common stock.

Parcrest International (“Parcrest”) served as the Company’s placement agent in connection with the October 2025 Private Placement. The Company agreed to pay Parcrest $1,500, as follows: (a) $1,000 in cash and (b) October 2025 Common Warrants to purchase up to 4,000,000 shares of the Company’s common stock at an exercise price of $0.5335 per share (the “Placement Agent Warrants”). Parcrest has agreed that it shall not sell, transfer, assign, pledge, or otherwise dispose of any of the Placement Agent Warrants or the warrant shares underlying the Placement Agent Warrants for a period of six months following their issuance date, except with the prior written consent of both the Company and the Lead Investor (as defined below in Note 9).